• Nazareno Galvalisi, Vanina Pagotto, Valeria Tudanca, Paola Brunetti, Carla Tornatore, Lucila Villar, Francisco Allalla, Héctor Ferraro, Alejandro Schejtman, and Flavio Rotryng.
• Servicio de Emergencias, Sanatorio Finochietto, Buenos Aires, Argentina. E-mail: nazareno.galvalisi@gmail.com.
• Medicina (B Aires). 2022 Jan 1; 82 (5): 659666659-666.

Introductionthere is evidence on the effectiveness and safety of tocilizumab (TZC) used in combination with systemic corticosteroids for severe SARS-CoV-2 pneumonia treatment. The purpose of this study was to describe epidemiological, clinical, and laboratory features as well as clinical outcome of patients receiving this combination therapy compared with those receiving only corticosteroids.Methodsa retrospective cohort study, which included adults with severe SARS-CoV-2 pneumonia, was conducted between March and August 2021. Enrolment included 101 patients, 46 with corticosteroids and 55 with corticosteroids plus tocilizumab.Resultsmedian age was 58 years old and 63.9% were females. High blood pressure was present in 36.1% and obesity in 54.6%. Survival in the cohort was 81.4%, with a median hospital stay of 19.0 days. Secondary infections were present in 47.4% of the cohort. Patients in the TZC group had a lower C reactive protein (CRP) at discharge, lower rate of multiple organ failure, better functional status at discharge and shorter hospital stay. In a bivariate analysis, no differences were found in mortality rate and secondary infections occurrence. When assessing clinical status as per WHO Ordinal Scale there was a significant difference in its variability from worsening to discharge (or 14 days), evidencing a better functional status in patients receiving TCZ.Discussionwe were able to demonstrate its efficacy in reducing inflammatory biomarkers and a trend towards fewer days of hospitalization, with no impact on mortality.

21 keywords...

hide…